Additionally, the CCl4-induced hepatic expression of pro-inflammatory genes, as demonstrated by IHC, Western blotting and qRT-PCR, was also significantly reduced by GPR65 inhibitor in vivo (Additional file 1: Fig. S23b, d, e), indicating that GPR65 inhibitor has the potential for clinical transformation in the treatment of hepatic fibrosis. The gene discussed is GPR65; the disease is Hepatic fibrosis.